Accessibility Menu
Travere Therapeutics Stock Quote

Travere Therapeutics (NASDAQ: TVTX)

$27.48
(-1.2%)
-0.32
Price as of October 22, 2025, 4:00 p.m. ET

KEY DATA POINTS

Current Price
$27.48
Daily Change
(-1.2%) $0.32
Day's Range
$26.79 - $28.24
Previous Close
$27.48
Open
$27.8
Beta
1.16
Volume
1,157,809
Average Volume
2,051,934
Market Cap
2.5B
Market Cap / Employee
$27.80M
52wk Range
$12.91 - $28.69
Revenue
-
Gross Margin
0.82%
Dividend Yield
N/A
EPS
-$2.04
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Travere Therapeutics Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
TVTX+53.59%+31.88%+5.69%+440%
S&P+15.06%+95.03%+14.29%+366%

Travere Therapeutics Company Info

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$114.45M111.5%
Gross Profit$98.91M137.1%
Gross Margin86.42%9.3%
Market Cap$1.31B110.0%
Market Cap / Employee$3.41M0.0%
Employees3851.3%
Net Income-$12.76M81.7%
EBITDA$1.37M102.4%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$75.15M132.7%
Accounts Receivable$38.72M58.3%
Inventory4.1-31.6%

Liabilities

Q2 2025YOY Change
Long Term Debt$325.14M-18.3%
Short Term Debt$74.43M1341.7%

Ratios

Q2 2025YOY Change
Return On Assets-30.55%29.0%
Return On Invested Capital-57.86%-9.8%

Cash Flow

Q2 2025YOY Change
Free Cash Flow$4.75M111.8%
Operating Free Cash Flow$4.98M112.4%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book-35.79-44.5626.5340.03374.00%
Price to Sales5.356.215.793.949.95%
Price to Tangible Book Value-8.09-10.08-34.91-18.51-19.79%
Enterprise Value to EBITDA-27.09-31.30-55.621022.28-8208.93%
Return on Equity-279.9%-246.7%-422.7%-705.7%21.13%
Total Debt$402.43M$401.58M$400.46M$399.57M-0.91%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.